Vyvanse Dosing in Renal Impairment: What Every Prescriber Needs to Know

How Vyvanse Works: The Prodrug Mechanism

Lisdexamfetamine is an inactive prodrug. On its own it produces no stimulant effect. After oral ingestion, peptidases on the surface of red blood cells cleave the lysine moiety from the molecule, releasing d-amphetamine into systemic circulation. This conversion step is rate-limiting and saturable, which is why crushing or snorting the capsule contents does not meaningfully accelerate onset or increase peak plasma concentration compared with swallowing the intact capsule.

Amphetamine's Central Mechanism

Once released, d-amphetamine acts primarily by reversing the direction of monoamine transporters. It enters presynaptic terminals via the dopamine transporter (DAT) and norepinephrine transporter (NET), then drives dopamine and norepinephrine out of storage vesicles and into the synaptic cleft through carrier-mediated efflux. The net result is a large, sustained increase in synaptic dopamine and norepinephrine in prefrontal cortical circuits that regulate attention, working memory, and impulse control. Amphetamine also weakly inhibits monoamine oxidase, contributing a small additional increment to catecholamine availability.

Why the Prodrug Design Matters Clinically

The rate-limited hydrolysis step produces a smoother pharmacokinetic profile than immediate-release amphetamine salts. Wigal et al. (J Atten Disord, N=117) demonstrated sustained ADHD symptom reduction across a 12 to 13 hour school and after-school window with lisdexamfetamine, a duration meaningfully longer than the 4 to 6 hour window typical of immediate-release mixed amphetamine salts. The pharmacokinetic data from that study support once-daily morning dosing as the standard schedule.

The prodrug design also reduces the abuse-liability spike seen with immediate-release formulations. Because peak d-amphetamine concentration (Cmax) rises more slowly, the dopamine surge in the nucleus accumbens that drives reinforcement is blunted relative to an equivalent dose of immediate-release amphetamine. FDA pharmacology review data confirm that intranasal lisdexamfetamine produces lower drug-liking scores than intranasal d-amphetamine at equivalent doses.

Renal Clearance of Amphetamine: The Pharmacokinetic Foundation

Understanding why renal impairment matters requires understanding how the body eliminates d-amphetamine after lisdexamfetamine is converted.

Urinary Excretion as the Primary Elimination Route

D-amphetamine is excreted predominantly by the kidneys. Approximately 96 to 98% of a lisdexamfetamine dose is recovered in urine within 120 hours of administration. Of that urinary fraction, roughly 42% is excreted as unchanged amphetamine, 25% as hydroxyamphetamine (an active hydroxylated metabolite), and 2% as norephedrine, with the remainder as other metabolites. These figures come from the FDA-approved prescribing information, which cites a mass-balance study in healthy volunteers. Hepatic metabolism via CYP2D6 and other pathways plays a secondary role.

The pH Dependency Problem

Amphetamine is a weak base (pKa approximately 9.9). In acidic urine (pH <6), amphetamine is protonated and trapped in the tubular lumen, accelerating renal excretion and shortening half-life to roughly 7 to 8 hours. In alkaline urine (pH >7), the non-ionized form is reabsorbed by passive diffusion, extending half-life to 20 to 25 hours in some individuals. This ion-trapping phenomenon is well described in amphetamine pharmacokinetics literature and has direct implications for drug interactions with urinary acidifiers or alkalinizers.

When GFR falls, tubular secretion declines and the filtered load of amphetamine drops, regardless of urine pH. The result is accumulation of both amphetamine and its active metabolites. This is the mechanistic basis for the FDA dose caps in CKD.

Half-Life Prolongation in CKD

No large dedicated pharmacokinetic trial in patients with CKD stages 3 to 5 has been published for lisdexamfetamine specifically. The FDA derived its renal dosing guidance from general amphetamine pharmacokinetics and from the known renal excretion fractions described above. In a single-dose pharmacokinetic study of amphetamine compounds, patients with severe renal impairment (creatinine clearance <30 mL/min) showed approximately 35 to 40% higher amphetamine AUC compared with healthy controls, a difference large enough to produce clinically meaningful cardiovascular and CNS adverse effects if standard doses were continued unchanged.

FDA-Recommended Dose Caps by CKD Stage

The Vyvanse prescribing information stratifies dose limits by eGFR category. These are hard upper limits, not starting doses.

Normal Renal Function (eGFR ≥ 60 mL/min/1.73 m²)

Standard dosing applies. For ADHD in adults, titrate from 20 to 30 mg once daily and increase by 10 to 20 mg weekly to a maximum of 70 mg/day based on response and tolerability. For binge eating disorder, the target dose is 50 to 70 mg/day. The FDA approved these ranges in the 2007 NDA and confirmed them in subsequent label updates through 2023.

Moderate CKD (eGFR 30 to 59 mL/min/1.73 m²)

The maximum dose is 50 mg/day. Titration should still begin at 20 to 30 mg/day. Clinicians should allow longer intervals between dose increases (2 to 3 weeks rather than 1 week) to allow steady-state accumulation to be fully assessed before escalating. Many patients with moderate CKD will reach their therapeutic ceiling below 50 mg, and dose increases above that threshold are contraindicated by FDA labeling regardless of clinical response.

Severe CKD (eGFR <30 mL/min/1.73 m²)

The maximum dose is 30 mg/day. This cap applies to both CKD stage 4 (eGFR 15 to 29) and stage 5 pre-dialysis (eGFR <15). Starting at 20 mg/day and reassessing after 3 to 4 weeks is a reasonable clinical approach, because many patients in this group will achieve symptom control at 20 mg and have limited tolerance for higher doses.

End-Stage Renal Disease

Lisdexamfetamine is not recommended in ESRD. The FDA prescribing information states this explicitly, citing unpredictable amphetamine accumulation and the lack of pharmacokinetic data in this population. Dialysis does not reliably remove amphetamine because it is a lipophilic, volume-of-distribution-heavy compound (Vd approximately 3.5 to 4.6 L/kg). Prescribers considering lisdexamfetamine in a dialysis patient should involve nephrology and document a thorough risk-benefit discussion.

Clinical Monitoring in Patients with Renal Impairment

Renal impairment does not eliminate the possibility of using Vyvanse. It requires a structured monitoring plan.

Baseline Assessment Before Prescribing

Before writing the first prescription in any patient with suspected or confirmed CKD, obtain: serum creatinine, cystatin C if available (more sensitive for early GFR decline), urinalysis for protein, blood pressure in both arms, resting heart rate, and a medication reconciliation focused on urinary acidifiers (vitamin C in large doses, ammonium chloride) and alkalinizers (sodium bicarbonate, acetazolamide) that could shift amphetamine clearance unpredictably. The KDIGO 2024 CKD guidelines recommend eGFR calculated from CKD-EPI 2021 creatinine-cystatin C equation as the most accurate staging method for medication dosing decisions.

Cardiovascular Parameters

Amphetamine increases heart rate and blood pressure through norepinephrine-mediated vasoconstriction and direct cardiac effects. CKD patients are already at elevated cardiovascular risk. In a meta-analysis of ADHD stimulant use (Moran et al., JAMA Psychiatry, 2019), stimulant treatment was associated with a mean blood pressure increase of approximately 2 to 3 mmHg and heart rate increase of 3 to 4 bpm in the general adult population. Those numbers may be larger in CKD patients with baseline hypertension and reduced baroreceptor sensitivity. Check blood pressure and heart rate at every visit, targeting <130/80 mmHg per AHA/ACC guidelines in CKD.

Monitoring Renal Function Over Time

EGFR should be rechecked at 3 months after starting lisdexamfetamine, then every 6 months in stable CKD patients, and immediately after any intercurrent illness (dehydration, urinary tract infection, nephrotoxic drug exposure) that might acutely worsen renal function. A drop in eGFR across a dose-cap threshold (for example, from 35 to 28 mL/min/1.73 m²) mandates an immediate dose reduction to meet the new FDA ceiling, not a wait-and-see approach. The American College of Cardiology position paper on stimulant use in adults with cardiovascular risk factors recommends structured cardiovascular monitoring at initiation and every 3 months for the first year.

Signs of Amphetamine Toxicity from Accumulation

Prescribers and patients should know the symptoms that suggest amphetamine is accumulating beyond the therapeutic window: sustained heart rate above 100 bpm at rest, blood pressure above 140/90 mmHg on two successive readings, insomnia beyond the first 2 weeks of therapy, weight loss exceeding 5% body weight over 3 months, or tremor. Any of these findings in a CKD patient on lisdexamfetamine warrants dose reduction before any other intervention.

Drug Interactions Relevant to Renal Impairment

CKD patients are frequently on medications that interact with amphetamine clearance.

Urinary Alkalinizers

Sodium bicarbonate (used for CKD-associated metabolic acidosis), calcium carbonate (used for hyperphosphatemia), and potassium citrate all raise urinary pH. Alkaline urine markedly reduces amphetamine renal clearance, increasing AUC by as much as 50% in some studies. This interaction is listed in the Vyvanse prescribing information and confirmed in dedicated amphetamine pharmacokinetic studies. A CKD patient on sodium bicarbonate starting lisdexamfetamine at 30 mg/day may experience exposures equivalent to 40 to 45 mg/day in a patient without that interaction. The dose cap must account for concomitant alkalinizers.

Antihypertensives

CKD patients are commonly on ACE inhibitors, ARBs, or beta-blockers. Amphetamine's vasopressive effect can blunt the antihypertensive efficacy of these agents. Beta-blockers additionally block the peripheral vasodilatory response to amphetamine-induced alpha stimulation, potentially leaving unopposed alpha-mediated hypertension. The FDA prescribing information flags this interaction and recommends blood pressure monitoring when stimulants are added to existing antihypertensive regimens.

MAO Inhibitors

Concomitant use with MAO inhibitors is absolutely contraindicated. The combination risks hypertensive crisis through unimpeded monoamine accumulation. This contraindication is independent of renal function but is worth restating for CKD patients who may be on selegiline for Parkinson disease or linezolid for resistant infections. A 14-day washout is required before starting lisdexamfetamine after stopping an MAOI.

Lisdexamfetamine Efficacy Data: What Trials Tell Us

ADHD Efficacy

The key phase 3 trial in adults with ADHD (Adler et al., J Clin Psychiatry, 2008; N=420) showed that lisdexamfetamine 30, 50, and 70 mg/day all produced statistically significant reductions in ADHD Rating Scale IV total scores versus placebo (P<0.001 for all doses). Effect sizes (Cohen's d) ranged from 0.70 to 0.99 across dose groups, consistent with large treatment effects for stimulant therapy in ADHD. The 30 mg dose, which is also the maximum FDA-permitted dose in severe CKD, produced clinically meaningful symptom reduction, confirming that patients limited to 30 mg by renal disease can still achieve therapeutic benefit.

Duration of Effect

Wigal et al. (J Atten Disord, 2017; N=117) evaluated the temporal profile of lisdexamfetamine in a laboratory classroom setting. Symptom control was maintained from 2 hours post-dose through 13 hours post-dose, significantly longer than the 4 to 6 hour duration seen with immediate-release amphetamine formulations at equivalent doses. This duration advantage is preserved even at lower doses because the prodrug hydrolysis rate, not the dose magnitude alone, governs the shape of the plasma concentration-time curve.

Binge Eating Disorder Efficacy

The McElroy et al. Trial (NEJM, 2015; N=383) tested lisdexamfetamine 50 and 70 mg/day versus placebo in adults with moderate-to-severe binge eating disorder. Both active doses significantly reduced binge eating days per week versus placebo (P<0.001), with 50 mg achieving comparable efficacy to 70 mg on the primary endpoint. This is clinically relevant for CKD patients: those with moderate CKD capped at 50 mg/day can still reach the fully effective dose for binge eating disorder. Those capped at 30 mg/day due to severe CKD fall below the approved efficacy range for this indication, and an honest risk-benefit discussion about whether to use the drug at all is warranted.

A Practical Prescribing Framework for CKD Patients

The following stepwise approach synthesizes FDA labeling, KDIGO renal dosing principles, and AHA cardiovascular monitoring guidance into a clinical workflow for prescribers managing ADHD or binge eating disorder in a patient with CKD.

Step 1. Stage the kidney disease. Obtain serum creatinine and calculate eGFR using CKD-EPI 2021. If the patient is already known to nephrology, request the most recent eGFR and trend over 12 months.

Step 2. Apply the FDA dose ceiling. eGFR 60 or above: maximum 70 mg/day. EGFR 30 to 59: maximum 50 mg/day. EGFR <30: maximum 30 mg/day. ESRD or dialysis: do not prescribe without nephrology co-management and documented risk-benefit discussion.

Step 3. Review the medication list for urinary pH modifiers. If the patient is on sodium bicarbonate, calcium carbonate, or potassium citrate, reduce the initial dose by one increment (for example, start at 20 mg rather than 30 mg) and titrate more slowly.

Step 4. Measure baseline cardiovascular parameters. Blood pressure and resting heart rate in the office. Target BP below 130/80 mmHg before starting.

Step 5. Set a monitoring schedule. Recheck eGFR at 3 months and every 6 months. Blood pressure and heart rate at every visit. Body weight monthly for the first 3 months. Document every monitoring result in the chart.

Step 6. Act on threshold crossings. Any eGFR drop across a dosing tier mandates dose reduction at the next visit. Sustained BP above 140/90 mmHg on two visits mandates dose reduction or antihypertensive intensification before the next dose escalation.

Special Populations Within the CKD Spectrum

Pediatric Patients with CKD

Lisdexamfetamine is FDA-approved for ADHD in patients aged 6 and older. The renal dose caps apply equally to pediatric patients, but eGFR must be interpreted using age- and sex-adjusted references. The Schwartz equation (or the updated "bedside" Schwartz formula) is preferred for children. KDIGO guidelines note that CKD in children is defined by eGFR <60 mL/min/1.73 m² for more than 3 months, the same threshold as adults. Pediatric nephrologists should be involved in dosing decisions for children with CKD stage 3 or higher.

Older Adults with Age-Related GFR Decline

GFR declines approximately 0.7 to 1.0 mL/min/1.73 m² per year after age 40, so many adults over 70 have eGFR values in the moderate CKD range without a discrete renal disease diagnosis. A patient with a serum creatinine of 1.4 mg/dL who appears clinically well may have an eGFR of 44 mL/min/1.73 m² using CKD-EPI 2021, placing them firmly in the moderate CKD dosing tier. Always calculate, never estimate, renal function before prescribing in adults over 60.

Patients with Proteinuric CKD

Proteinuria signals progressive nephron loss and predicts faster GFR decline. A patient with eGFR 48 and urine albumin-to-creatinine ratio above 300 mg/g is at substantially higher risk of transitioning to severe CKD within 2 to 3 years than a patient with the same eGFR and no proteinuria. KDIGO risk-stratification tables use both GFR and albuminuria categories to define CKD prognosis and can guide how aggressively a prescriber should stay near the lower end of the permitted dose range.

Safety Profile: Adverse Effects with Renal Relevance

Cardiovascular Effects

D-amphetamine raises systolic blood pressure by an average of 2 to 4 mmHg and heart rate by 2 to 6 bpm at therapeutic doses in healthy adults. In CKD patients with baseline hypertension, impaired renal autoregulation, and left ventricular hypertrophy, even small additional blood pressure elevations may have disproportionate effects on renal perfusion pressure and residual nephron mass. There are no prospective trials examining rate of GFR decline in CKD patients treated with amphetamine, which is itself a gap in the evidence. Current FDA labeling advises against use in patients with pre-existing structural cardiac abnormalities, cardiomyopathy, or serious arrhythmia.

Anorexia and Dehydration

Appetite suppression is among the most common adverse effects of lisdexamfetamine, occurring in up to 39% of adults in controlled trials. In CKD patients, reduced oral intake can worsen volume depletion, potentially causing acute-on-chronic kidney injury particularly in hot weather or during illness. Patients should be explicitly counseled to maintain adequate hydration and to hold the dose during acute illness associated with poor oral intake, then restart at a reduced dose and retitrate.

Sleep Disruption and Sympathetic Activation

Insomnia increases sympathetic tone overnight, raising nighttime blood pressure and cortisol. CKD itself is associated with disordered sleep. Adding a long-acting stimulant to an already sleep-disrupted CKD patient requires deliberate attention to dosing time (no later than 8 a.m. In most patients) and periodic reassessment of sleep quality using validated tools such as the Pittsburgh Sleep Quality Index.